Skip to main content
MyPeptideMatch

Pancragen

Research Only

Bioregulator

Blood sugar regulation (animal and small human studies)Pancreatic functionAnti-aging
Last reviewed October 2026MyPeptideMatch Team

What Is Pancragen?

Pancragen is a four-amino-acid peptide: lysine, glutamic acid, aspartic acid and tryptophan, written Lys-Glu-Asp-Trp or KEDW. Several papers, and the developers' own reference table, use a version with an amidated end, written KEDW-NH2.[1] It comes from Vladimir Khavinson's "peptide bioregulator" program at the St. Petersburg Institute of Bioregulation and Gerontology, and the developers describe it as a regulator of pancreatic function.[1]

The design idea was specific. Khavinson reported that several insulin-releasing hormones share a common four-amino-acid fragment, and synthesized KEDW as a stable copy of it.[2] That makes Pancragen unusual among the bioregulators: it was built to mimic a known hormone motif, not just derived from a tissue extract.

Pancragen also has more research than most of its siblings, including small studies in monkeys and in older people. But all of it comes from Khavinson's group and its collaborators, most of it is in cells and animals, the human studies are small and not described as randomized or blinded, and none of it has been independently replicated.

Key Takeaways
  • Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW), usually amidated, developed by Khavinson's group as a pancreas "bioregulator."
  • In cell studies it raised markers of pancreatic cell differentiation and activity; in diabetic rats it lowered blood glucose.
  • Two small studies in old rhesus monkeys used 50 µg per animal per day, injected into muscle, for 10 days.
  • Two small studies in older people reported lower glucose and insulin resistance; one used 500 µg twice a day for 4 weeks in 12 people.
  • It is not FDA-approved, no trial appears on ClinicalTrials.gov (searched October 2026), and none of our directory clinics currently lists it.
Common NamePancragen (also spelled Pankragen, Pancragene)
SequenceLys-Glu-Asp-Trp (KEDW); usually amidated, KEDW-NH2
Formula / Molecular WeightC26H37N7O8 (amidated) / about 576 Da
ClassSynthetic short peptide ("peptide bioregulator")
Developed byKhavinson group, St. Petersburg Institute of Bioregulation and Gerontology
Primary Research AreasPancreatic cell aging, diabetes models in rats, glucose tolerance in old monkeys and older adults
Human StudiesTwo small studies from the developers' network; none on ClinicalTrials.gov
FDA StatusNot approved for any indication
Forms SoldLyophilized "research use only" vials, commonly 20 mg
Typical DoseNo established dose; research doses listed below

How Does Pancragen Work?

The developers propose that very short peptides cross cell and nuclear membranes and bind DNA or histone proteins, switching genes on or off.[1] For Pancragen, the DNA-binding part comes from computer modeling and test-tube work: modeling placed KEDW in both grooves of DNA, with a preferred binding sequence of GGCAG,[10] and the 2005 paper proposed that it acts on the insulin gene's promoter.[2] Nobody has shown that binding inside a living pancreatic cell.

The measured effects in cells are more concrete:

  • Differentiation genes. In "young" and "aged" cultures of pancreatic cells, Pancragen raised the differentiation factors Pdx1 and Ptf1a in acinar (digestive-enzyme) cells and Pdx1, Pax6, Pax4, Foxa2 and Nkx2.2 in islet (hormone-producing) cells.[6] In human embryonic pancreatic cells, it raised CXCL12 and Hoxa3, with a bigger effect in aged cultures.[7]
  • Cell activity and survival. In aged human pancreatic cell cultures, it increased the proliferation markers Ki67 and PCNA and the survival protein Mcl1, and lowered p53.[8]
  • DNA methylation. A related study linked age-related changes in methylation of the PDX1, PAX6 and NGN3 gene promoters to their expression in pancreatic cells, and reported that KEDW affected those patterns.[9]
  • Tissue growth. In rat organ cultures, Pancragen at 0.05 ng/mL stimulated growth of pancreatic tissue from young and old animals.[15]

What the Clinical Evidence Actually Shows

Rat studies. In rats with alloxan-induced diabetes, KEDW partly restored insulin production, and the glucose curve looked similar to that of normal animals.[2] In rats with streptozotocin-induced diabetes, Pancragen given by mouth had a pronounced glucose-lowering effect during treatment; given by injection into muscle, it normalized the stickiness of small blood vessel linings but did not change their permeability.[3] A third study reported improved pancreatic tissue structure in diabetic rats,[4] and a fourth measured apoptosis-related metabolic markers in diabetic and aging rats.[5] These abstracts are short and give few numbers.

Old rhesus monkeys. Two reports from the Research Institute of Medical Primatology in Sochi, co-authored with Khavinson, are the strongest animal evidence. Old female monkeys given 50 µg of Pancragen a day by intramuscular injection for 10 days cleared glucose faster after a glucose load, and their insulin and C-peptide responses moved toward those of young animals. Part of the effect remained three weeks after stopping.[11] In the second report, five old monkeys got Pancragen and four got the diabetes drug glimepiride (4 mg a day by mouth). Both lowered resting blood glucose. Glimepiride had a stronger, more delayed glucose-lowering effect and raised C-peptide without changing insulin; Pancragen normalized both insulin and C-peptide.[12] Nine animals is a very small study.

Older adults. Two studies from the Institute of Gerontology in Kyiv, both co-authored with Khavinson:

  • In 2011, researchers examined 33 older people with type 2 diabetes and 30 healthy older controls. In the diabetic patients, Pancragen lowered fasting glucose, glucose during a glucose tolerance test, insulin levels and an insulin resistance index; diabetic patients who did not receive it showed no change.[13] The abstract does not say how many people received Pancragen, at what dose, or whether they were assigned at random.
  • In 2013, 12 older adults with impaired glucose tolerance took Pankragen-forte at 500 µg twice a day for 4 weeks. Glucose during the tolerance test fell significantly in half of them, and the authors also reported improvements in blood lipids, blood vessel function and platelet stickiness.[14] No control group is described in the abstract.

Neither study was registered on ClinicalTrials.gov, and neither abstract describes randomization, blinding or a placebo.

What the Evidence Does Not Show

  • That Pancragen works in a controlled trial. There is no randomized, placebo-controlled human trial.
  • Durable benefit. The longest human course was 4 weeks. No study followed HbA1c or diabetes outcomes over months or years.
  • Comparison with standard care. The only comparison with an approved drug was in nine monkeys.[12] Nothing compares it with metformin, GLP-1 drugs or lifestyle change in people.
  • A dose. No study compared doses.
  • Safety. The monkey authors called it "safe," but in nine animals over 10 days. There is no systematic human safety data.
  • Independent confirmation. Every Pancragen study we found either lists Khavinson as an author or comes from his institute.

Typical Dosing — What the Research Has Used

No established dose

No controlled trial has established a safe or effective dose of Pancragen. The figures below are what specific studies used. They are not dosing guidance, and they do not convert into a personal dose.

People searching for a Pancragen dosage per day are usually looking for a number. These are the only numbers with a published source:

Pancragen Doses Used in Published Research

ParameterDoseRouteLengthResult reported
Old rhesus monkeys (Sochi, 2014)50 µg per animal per dayIntramuscular10 daysFaster glucose clearance; insulin and C-peptide normalized; partly lasted 3 weeks
Old rhesus monkeys vs. glimepiride (Sochi, 2015)50 µg per animal per day (5 animals)Intramuscular10 daysLower resting glucose; glimepiride lowered glucose more
Older adults with impaired glucose tolerance (Kyiv, 2013)500 µg twice a dayNot stated in abstract4 weeksLower glucose in 6 of 12 people
Older adults with type 2 diabetes (Kyiv, 2011)Not stated in abstractNot stated in abstractNot stated in abstractLower glucose, insulin and insulin resistance
Diabetic rats (2007)Not stated in abstractOral and intramuscularNot stated in abstractOral: lower glucose. Intramuscular: vessel lining effect

Sources: monkeys,[11][12] older adults,[13][14] rats.[3]

A few things stand out. The two human studies used different products and reported different details, and only one gives a dose. The monkey dose is per animal, not per kilogram, so it does not scale to a person in any simple way. And the rat work suggests the peptide may act when swallowed, which fits the 2005 claim that it was designed to resist digestive enzymes,[2] but no study has measured how much reaches the blood either way.

Pancragen is sold online as 20 mg research vials. Community schedules circulate for them, but none comes from a trial, and we do not publish a Pancragen protocol page.

Side Effects — What to Actually Expect

No study has reported a side effect profile for Pancragen in people. The two human studies did not report adverse events in their abstracts, which is not the same as reporting that there were none.

What can reasonably be said:

  • Low blood sugar is a plausible risk. Every animal and human study reports glucose going down. If you take insulin, a sulfonylurea such as glimepiride, or another glucose-lowering drug, adding something that may lower glucose further is a reason to involve your prescriber.
  • Injection-related risks apply to any injected research peptide: redness, pain or swelling at the site, and infection if the product or technique isn't sterile.
  • Product quality is unverified. "Research use only" vials are not made under drug manufacturing rules.

Do not stop or reduce a prescribed diabetes medicine to try Pancragen. The evidence is nowhere near strong enough to replace treatments that have been tested in large trials.

Regulatory & Access Status

Access status as of October 2026

Pancragen is not FDA-approved for any indication and has no entry in Drugs@FDA or DailyMed. None of the clinics on our directory currently lists Pancragen among the peptides it offers.

In the US, Pancragen is sold by research chemical vendors as vials labeled "not for human consumption." The 2013 human study used a product called Pankragen-forte, which the abstract describes only as a tetrapeptide preparation. We could not confirm its exact contents or form.[14]

Sourcing & Safety

If you decide to buy Pancragen anyway, these checks matter more than the brand name:

  • An independent certificate of analysis (COA) from a named third-party lab, dated, for the specific batch you receive.
  • HPLC purity of at least 98%, plus mass spectrometry confirming Lys-Glu-Asp-Trp at about 576 Da. Bioregulator sequences are often mixed up online, so check the sequence on the COA.
  • Sterility and endotoxin testing for anything you plan to inject.

Treat as red flags: claims that Pancragen treats or reverses diabetes, advice to stop diabetes medicines, no third-party COA, and references to human studies that can't be found in PubMed.

What Makes Pancragen Different

Most Khavinson bioregulators are tied to an organ mainly by the developers' theory. Pancragen has a more specific rationale (a copy of a fragment shared by insulin-releasing hormones),[2] a primate study with an active comparator,[12] and glucose measured in people.[13][14] That puts it ahead of siblings like Ovagen, which has no human data at all. It is still far behind any approved diabetes drug.

It also shares its first three amino acids, Lys-Glu-Asp, with Livagen (KEDA) and Testagen (KEDG), which the developers assign to the liver and the male reproductive system.[1]

Pancragen vs. Approved Glucose-Lowering Peptides

ParameterPancragenSemaglutideLiraglutide
Length4 amino acids31 amino acids (modified GLP-1 analog)31 amino acids (modified GLP-1 analog)
Proposed actionGene regulation in pancreatic cellsGLP-1 receptor agonistGLP-1 receptor agonist
Largest human studyTwo small studies; 12 people in the one that reports numbersLarge randomized trialsLarge randomized trials
FDA statusNot approvedApprovedApproved

FAQ

What is Pancragen peptide?

Pancragen is a synthetic four-amino-acid peptide, lysine-glutamic acid-aspartic acid-tryptophan (Lys-Glu-Asp-Trp, or KEDW), usually made with an amidated end (KEDW-NH2). It was developed by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology as a 'peptide bioregulator' for the pancreas. It is not an approved drug in the US.

What is Pancragen peptide used for?

It is marketed for pancreatic function and blood sugar control, mainly in older adults. The research behind that is cell-culture work on pancreatic cells, studies in diabetic rats, two small studies in old rhesus monkeys, and two small studies in older people with type 2 diabetes or impaired glucose tolerance, all from the developers' network.

What is the Pancragen dosage per day?

No dose has been established by a controlled trial. The published studies used 50 µg per animal per day by intramuscular injection for 10 days in old monkeys, and 500 µg twice a day for 4 weeks in 12 older adults with impaired glucose tolerance. Those are research figures, not dosing guidance.

What are the benefits of Pancragen?

In the developers' studies, Pancragen lowered blood glucose in diabetic rats, normalized insulin and C-peptide responses in old monkeys, and lowered glucose and insulin resistance in small groups of older people. None of these studies was a large randomized, placebo-controlled trial, and none has been repeated by an independent lab.

Is Pancragen FDA approved?

No. Pancragen has no FDA approval for any use and does not appear in Drugs@FDA or DailyMed. It is not a substitute for approved diabetes medicines.

Is there a Pancragen protocol?

The only published protocols are the research schedules: a 10-day intramuscular course in monkeys and a 4-week twice-daily course in a small human study. Any other protocol you see online is community-made and has not been tested.

If your interest in Pancragen is blood sugar or weight, the peptides with real trial evidence are semaglutide, tirzepatide and liraglutide; see also our guide to weight loss treatments. From the bioregulator family, Epithalon has the deepest research, and Livagen, Ovagen, Pinealon and Vilon are its most searched relatives. For the broader category, see anti-aging and longevity.

References

  1. Khavinson V, Linkova N, Kozhevnikova E, et al. "Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers." Int J Mol Sci. 2022;23(14):7733. PMID: 35887081
  2. Khavinson VK. "Effect of tetrapeptide on insulin biosynthesis in rats with alloxan-induced diabetes." Bull Exp Biol Med. 2005;140(4):452-454. PMID: 16671579
  3. Khavinson VKh, Gavrisheva NA, Malinin VV, et al. "Effect of pancragen on blood glucose level, capillary permeability and adhesion in rats with experimental diabetes mellitus." Bull Exp Biol Med. 2007;144(4):559-562. PMID: 18642713
  4. Kvetnoi IM, Ryzhak AP, Kostyuchek IN, et al. "Effect of tetrapeptide pancragene on functional morphology of the pancreas in rats with experimental diabetes mellitus." Bull Exp Biol Med. 2007;143(3):368-371. PMID: 18225766
  5. Khavinson VKh, Gapparov MM, Sharanova NE, et al. "Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide." Bull Exp Biol Med. 2010;149(3):351-353. PMID: 21246099
  6. Khavinson VKh, Durnova AO, Polyakova VO, et al. "Effects of pancragen on the differentiation of pancreatic cells during their ageing." Bull Exp Biol Med. 2013;154(4):501-504. PMID: 23486591
  7. Khavinson VKh, Linkova NS, Polyakova VO, et al. "Peptides tissue-specifically stimulate cell differentiation during their aging." Bull Exp Biol Med. 2012;153(1):148-151. PMID: 22808515
  8. Khavinson VKh, Sevost'ianova NN, Durnova AO, et al. "Tetrapeptide stimulates functional activity of the pancreatic cells in aging." Adv Gerontol. 2012;25(4):680-684. PMID: 23734516
  9. Ashapkin VV, Linkova NS, Khavinson VKh, et al. "Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells." Biochemistry (Mosc). 2015;80(3):310-322. PMID: 25761685
  10. Tarnovskaya SI, Yakutseni PP, Khavinson VKh. "Study of interactions between DNA and tetrapeptides using methods of molecular mechanics." Bull Exp Biol Med. 2014;156(5):689-693. PMID: 24770759
  11. Goncharova ND, Ivanova LG, Oganian TÉ, et al. "Impact of tetrapeptide pancragen on endocrine function of the pancreas in old monkeys." Adv Gerontol. 2014;27(4):662-667. PMID: 25946840
  12. Goncharova ND, Ivanova LG, Oganyan TE, et al. "Correction of impaired glucose tolerance using tetrapeptide (Pancragen) in old female rhesus monkeys." Adv Gerontol. 2015;28(3):579-585. PMID: 28509500
  13. Korkushko OV, Khavinson VKh, Shatilo VB, et al. "Prospects of using pancragen for correction of metabolic disorders in elderly people." Bull Exp Biol Med. 2011;151(4):454-456. PMID: 22448364
  14. Korkushko OV, Chizhova VP, Shatilo VB, et al. "The tetrapeptide pankragen forte efficiency in elderly people with prediabetic state." Adv Gerontol. 2013;26(2):297-308. PMID: 28976155
  15. Zakutskiĭ AN, Chalisova NI, Ryzhak GA, et al. "The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats." Adv Gerontol. 2006;19:93-96. PMID: 17152728

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.

Where to Buy Pancragen for Research

Research Use Only — not intended for human consumption

1
Biolongevity LabsTop Rated
$94.97
Code MPM · 15% off
View Product
2
Eros Peptides
View Product

Research peptides are sold for laboratory use only and are not intended for human consumption.

Find Clinics Offering Pancragen

No clinics in our directory yet. Browse all clinics.

Find a Peptide Clinic Near You

Continue Reading

Articles about Pancragen and related topics

MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.